Targeted Drugs in Therapy of Gastric Cancer
Molecular changes revealed in gastric adenocarcinoma cells contribute both to isolation of different molecular subtypes and stimulated study of inhibitors acting on relevant signaling pathways in cell lines and xenograft models as well as patients with metastatic gastric cancer. However, good preclinical results were not always associated with clinical efficacy. Here, we review the main achievements and failures, future and obstacles towards introduction of targeted therapy into maintenance of patients with metastatic gastric cancer.